View Item 

Show simple item record

Effect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2
dc.contributor.authorMertens, W. C.en_US
dc.contributor.authorBramwell, V. H. C.en_US
dc.contributor.authorGwadry-Sridhar, Femidaen_US
dc.contributor.authorRomano, W.en_US
dc.contributor.authorBanerjee, D.en_US
dc.contributor.authorLala, P. K.en_US
dc.date.accessioned2006-04-10T15:07:18Z
dc.date.available2006-04-10T15:07:18Z
dc.date.issued1992-08-15en_US
dc.identifier.citationMertens, W. C., Bramwell, V. H. C., Gwadry-Sridhar, F., Romano, W., Banerjee, D., Lala, P. K. (1992/08/15)."Effect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2." The Lancet 340(8816): 397-398. <http://hdl.handle.net/2027.42/29902>en_US
dc.identifier.urihttp://www.sciencedirect.com/science/article/B6T1B-49K5GR4-MT/2/3c3f16f789e7048f2d0feb4cc208a6efen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/29902
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=1353559&dopt=citationen_US
dc.description.abstractPreclinical models of advanced melanoma have shown that chronic indomethacin therapy combined with interleukin 2 (IL-2) can eradicate experimental metastases. A phase II trial was done in patients with advanced melanoma. Indomethacin and ranitidine were begun at least one week before IL-2. Of the objective responses in 3 patients, 2 were achieved on ranitidine and indomethacin alone, before start of IL-2. Indomethacin and ranitidine may be responsible for some responses in melanoma patients previously attributed to IL-2.en_US
dc.format.extent505653 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherElsevieren_US
dc.titleEffect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Radiology, University of Michigan Medical Center, Ann Arbor, Ml, Swedenen_US
dc.contributor.affiliationotherDepartment of Medical Oncology, London Regional Cancer Centre and University of Western Ontario,, United Kingdomen_US
dc.contributor.affiliationotherDepartment of Medical Oncology, London Regional Cancer Centre and University of Western Ontario,, United Kingdomen_US
dc.contributor.affiliationotherDepartment of Medical Oncology, London Regional Cancer Centre and University of Western Ontario,, United Kingdomen_US
dc.contributor.affiliationotherDepartment of Pathology, University of Western Ontario, London, Ontario, Canada.en_US
dc.contributor.affiliationotherDepartment of Anatomy, University of Western Ontario, London, Ontario, Canada.en_US
dc.identifier.pmid1353559en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/29902/1/0000259.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1016/0140-6736(92)91474-Men_US
dc.identifier.sourceThe Lanceten_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
0000259.pdf
Size:
493.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.